What medical benefits are actually proven for cannabis-derived drugs?
The evidence supports modest benefits for a narrow set of conditions. A meta-analysis of randomized trials found that prescribed cannabinoids (like dronabinol and nabilone) produced a small but significant reduction in nausea and vomiting from chemotherapy (standardized mean difference -0.29, meaning a modest improvement over placebo) [1]. In HIV/AIDS patients, cannabinoids had a moderate effect on increasing body weight (standardized mean difference 0.57) [1]. For chronic pain, muscle spasticity, and refractory epilepsy (with CBD), the benefits are small to modest, and the evidence is strongest when these drugs are used as add-ons to standard treatments [5]. Importantly, evidence does NOT support cannabis for most other conditions like acute pain, insomnia, or mental disorders [1][5].
What are the real risks, and how big are they?
The risks are substantial and dose-dependent. High-potency cannabis (≥10% THC) is linked to a nearly doubled risk of psychotic symptoms (12.4% vs 7.1% for low-potency) and a 64% higher rate of generalized anxiety disorder (19.1% vs 11.6%) [1]. Daily inhaled cannabis use raises the risk of coronary heart disease (2.0% vs 0.9%), heart attack (1.7% vs 1.3%), and stroke (2.6% vs 1.0%) compared to non-daily use [1]. A large Canadian cohort study found that medical cannabis authorization was associated with a 44% increased risk of emergency visits or hospitalization for acute coronary syndrome or stroke (adjusted hazard ratio 1.44) [3]. Chronic use also impairs memory, attention, and executive function, with neuroimaging showing reduced hippocampal volume [4]. About 10% of all users develop cannabis dependence, and the rate is higher (29%) among those using for medical purposes [1][4].
How can clinicians and regulators separate benefit from abuse risk in practice?
The separation hinges on three things: product selection, patient screening, and monitoring. First, use only low-potency THC products (under 10% THC) or pure CBD, and avoid inhaled or high-potency cannabis [1]. Second, screen out patients with contraindications like pregnancy, schizophrenia, or ischemic heart disease, where risks likely outweigh benefits [1]. Third, monitor for signs of cannabis use disorder—a study found that 29% of medical users met criteria for this condition [1]. A key predictor of abuse potential is the patient's self-reported 'Willingness to Take Again'—this measure was more strongly linked to actual drug-taking behavior than the standard 'Drug Liking' rating in a study of daily cannabis users (odds ratio 1.04) [2]. Clinicians should discuss harm reduction: avoid combining cannabis with alcohol or benzodiazepines, use the lowest effective dose, and never drive after use [1].
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2025, 4 from 2024 or later, 2 in Q1 journals, collectively cited 158 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 49 papers retrieved from a database of over 500 million.
Sources used in this answer
Therapeutic Use of Cannabis and Cannabinoids
This 2025 JAMA review found that evidence supports cannabinoids only for HIV/AIDS anorexia, chemotherapy nausea, and pediatric seizures; high-potency cannabis (≥10% THC) doubles psychosis risk (12.4% vs 7.1%) and raises anxiety (19.1% vs 11.6%), and 29% of medical users develop cannabis use disorder.
Subjective drug-effect ratings predict cannabis self-administration in people who use cannabis daily
In a retrospective analysis of 89 daily cannabis users, the subjective rating 'Willingness to Take Again' was a stronger predictor of actual cannabis self-administration (odds ratio 1.04) than the standard 'Drug Liking' measure, suggesting a better abuse-potential assessment tool.
Medical cannabis authorization and the risk of cardiovascular events: a longitudinal cohort study
This longitudinal cohort study of 18,653 medical cannabis patients in Ontario found a 44% increased risk of emergency visits or hospitalization for acute coronary syndrome or stroke (adjusted hazard ratio 1.44) compared to matched controls, with the effect significant only in males.
Adverse Effects of Recreational and Medical Cannabis
This review reports that cannabis impairs memory, attention, and executive function, with chronic use linked to reduced hippocampal volume; up to 10% of users meet criteria for lifetime cannabis dependence, and earlier age of use increases neurocognitive deficits.
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits
This 2024 review found that medicinal cannabis provides small to modest benefits for chronic pain, spasticity, chemotherapy nausea, and refractory epilepsy (CBD), but evidence is inconclusive for mental disorders; safety is generally acceptable but includes risk of mild to moderate adverse effects and cannabis use disorder.